Email this page

Mandatory fields are marked with an asterisk [*].

Fill in your email details
1. * Your name:
2. * Your email address:
3. * Recipient name:
4. * Recipient email address:
Note: Smith & Nephew does not collect or make use of the email addresses or names provided here. They are only used to show the recipient who has sent the message.
Change the message if you want to
1. To: <recipient name> <address>
2. From: <sender name> <address>
3. Subject: <sender name> is sending you a link
4. Hi,
  I saw this on the Smith & Nephew site and thought you might be interested.
5. <sender name>
Visitor verfication
1. *Type the code shown

DUROLANE

DUROLANE Hyaluronic Acid is an HA product available in Europe and Canada and under review at the FDA. Its treatment regimen will require just one injection, which is a great advantage compared with current products, where three to five injections are required to achieve equivalent results. For patients and doctors this means that the risk of injection-related infections decreases and that the patient does not need to come back as often. DUROLANE is based on non-animal hyaluronic acid, which eliminates the risk of allergic reactions and the transmission of diseases from animals. DUROLANE will be approved for treatment of osteoarthritis of the knee initially, with an indication for treatment of the hip to follow.